Intellectual Property India Publishes Patent Application for '5-Htr1b Modulator For Use In The Treatment Of Solid Tumours' Filed by Leukos Biotech SL

MUMBAI, India, April 20 -- Intellectual Property India has published a patent application (202617003981 A) filed by Leukos Biotech SL, Barcelona, Spain, on Jan. 14, for '5-htr1b modulator for use in the treatment of solid tumours.'

Inventor(s) include Munoz Risueno, Ruth; Ruiz-Avila, Luis; Castro Palomino, Julio; and Camacho Gomez, Juan.

The application for the patent was published on April 17, under issue no. 16/2026.

According to the abstract released by the Intellectual Property India: "This invention relates to a new potent and selective compound that modulates serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compound is of utility in the treatment of cancer, in particular solid tumors."

The patent application was internationally filed on June 14, 2024, under International application No.PCT/EP2024/066582.

Disclaimer: Curated by HT Syndication.